Supplemental Table 2: Evaluation of different risk cutoffs within the "1 elevated value" group to characterize how well each cutoff identifies patients who require pharmacotherapy
Fields of Study & Subjects
Pharmaceutical Practices and Patient Outcomes
Lipoproteins and Cardiovascular Health
Blood Pressure and Hypertension Studies
Publication details
- Journal / source
- Zenodo (CERN European Organization for Nuclear Research)
- Publication date
- 17 January 2026